PharmTech Drug Digest 11.20
News|Articles|October 8, 2015

PaizaBio Introduces Aseptic Services for China Market

Contract manufacturer PiazaBio announces services for Western Pharma companies seeking to enter the China market.

PaizaBio, a contract manufacturer and marketing agent based in Albuquerque, NM, USA, has announced sterile injectable services for Western pharmaceutical companies seeking entry into China’s market.

PaizaBio reports in a company announcement that it has implemented processes and services to ensure quality, competitiveness, and transparency in China, including a training program for a qualified aseptic workforce; a digital and video production monitoring system; and lyophilization services.

The company’s manufacturing presence in China includes a 40,000-square-meter compound, encompassing a 25,000-square-meter production facility and 10,000-square-meter warehouse. Production equipment includes nine automated filling lines for vials, cartridges and syringes; 10 capping lines; a packaging facility with automated and manual options; four formulation tanks with a capacity of 3,000 liters; and laboratory facilities for testing, validation, analysis, and development. Additionally, the company offers clients expertise in Chinese regulatory compliance.

Soource: PaizaBio

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.